Professional technology integration to support the entire R&D process

Founded in 2018, Reqbio (Shanghai) Biotechnology Co., Ltd. is a comprehensive company specializing in proprietary biologics and contract research services for life sciences. Over the years, we have integrated resources and dedicated efforts to R&D, establishing a range of proprietary products and databases, including Drug Target Cell Libraries, Tracer Cell Libraries, and Gene Expression & Mutation Databases. Additionally, we have developed a suite of experimental CRO platforms covering gene editing, stable cell line generation, PCR detection, and NGS sequencing.
With innovation at the core of our strategy, we leverage cutting-edge cell function engineering technologies and a high-precision gene editing platform to build a comprehensive drug screening cell model system targeting key disease pathways such as kinases, GPCRs, and tumor immunology. We are committed to providing end-to-end support for global drug discovery, not only facilitating the development of novel targeted therapies but also advancing the understanding of cross-species gene functions and genetic drivers of human diseases. Building on these technological strengths, we continue to drive innovation in personalized molecular, cellular, and gene therapies.